Capture Vascular's proprietary platform technology, the MegaVac Mechanical Thrombectomy System, is uniquely designed to remove thrombus and emboli throughout the peripheral and coronary vasculature. The unique design and broad indications for use of the MegaVac Mechanical Thrombectomy System makes it appropriate for several key markets, with a total worldwide market opportunity greater than $500M. Capture’s initial focus is peripheral arterial disease and coronary arterial disease. The combination of just these two indications will address a global market of over 200,000 patients annually. Capture Vascular is managed by Telluride Medical Partners LLC.

CONTACT US:

WATCH IN ACTION

THE DEVICE

Capture Vascular is managed by Telluride Medical Partners LLC (TMP) comprised of business entrepreneurs and medical device startup experts who are experienced in combining both business and technical knowledge, upstream market identification, monetization strategies, and execution towards the development and growth of medical device companies. In addition to Capture Vascular, TMP currently manages the following innovative medtech companies and is actively seeking investors for each:

Relēver helps get rid of headaches 100% naturally by stretching the jaw muscles.

Nespiro has developed a new data-driven solution for mechanical ventilation weaning and prediction of post-extubation complications.

Nectero focuses on the development of early-stage treatment of abdominal aortic aneurysms.